Treatment of circulating CD34(+) cells with SDF-1alpha or anti-CXCR4 antibody enhances migration and NOD/SCID repopulating potential.
Exp. Hematol., Sep;30(9):1061-9 (2002)
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
Clin. Cancer Res., Nov;8(11):3383-93 (2002)
Decreased homing of retrovirally transduced human bone marrow CD34+ cells in the NOD/SCID mouse model.
Exp. Hematol., Apr;34(4):433-42 (2006)
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Oncologist., Jan;12(1):99-106 (2007)
Antimyeloma effects of a sesquiterpene lactone parthenolide.
Clin. Cancer Res., Mar;14(6):1814-22 (2008)
Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding.
Clin Lymphoma Myeloma., Oct;8(5):309-11 (2008)
Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma.
Am. J. Clin. Oncol., Jun;34(3):286-8 (2011)
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Br. J. Haematol., Aug;150(3):313-25 (2010)
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Biol. Blood Marrow Transplant., Jul;17(7):987-94 (2011)
Novel combination treatments targeting chronic myeloid leukemia stem cells.
Clin Lymphoma Myeloma Leuk., Apr;12(2):94-105 (2012)
Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables.
J. Clin. Oncol., Nov;21(22):4100-4 (2003)
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Leukemia and Lymphoma